CANDEL THERAPEUTICS, INC. (CADL) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $761.00K; Additional Paid in Capital, Common StockUSD $403.97M; Treasury Stock, ValueUSD $448.00K; Retained Earnings (Accumulated Deficit)USD $-278.15M.
- 2026-03-31: Common Stock, Value, IssuedUSD $733.00K; Additional Paid in Capital, Common StockUSD $376.99M; Treasury Stock, ValueUSD $448.00K; Retained Earnings (Accumulated Deficit)USD $-239.25M.
- 2025-12-31: Common Stock, Value, IssuedUSD $550.00K; Additional Paid in Capital, Common StockUSD $282.21M; Treasury Stock, ValueUSD $448.00K; Retained Earnings (Accumulated Deficit)USD $-230.39M.
- 2025-09-30: Common Stock, Value, IssuedUSD $550.00K; Additional Paid in Capital, Common StockUSD $280.91M; Treasury Stock, ValueUSD $448.00K; Retained Earnings (Accumulated Deficit)USD $-200.89M.
CANDEL THERAPEUTICS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Treasury Stock, Value USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Fair Value USD | Treasury Stock, Value, Acquired, Cost Method USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $761.00K | $403.97M | $448.00K | $-278.15M | $126.13M | 3 month · $2.01M 6 month · $3.59M | 3 month · $848.00K 6 month · $721.00K | (m) |
| 2026-03-31 | $733.00K | $376.99M | $448.00K | $-239.25M | $138.03M | 3 month · $1.58M | 3 month · $-127.00K | (m) |
| 2025-12-31 | $550.00K | $282.21M | $448.00K | $-230.39M | $51.92M | 12 month · $4.32M | 12 month · $-498.00K | (m) |
| 2025-09-30 | $550.00K | $280.91M | $448.00K | $-200.89M | $80.12M | 3 month · $1.16M 9 month · $3.11M | 3 month · $2.00K 9 month · $-581.00K | (m) |
| 2025-06-30 | $549.00K | $279.73M | $448.00K | $-189.62M | $90.21M | 3 month · $1.15M 6 month · $1.95M | 3 month · $-99.00K 6 month · $-583.00K | (m) |
| 2025-03-31 | $493.00K | $259.46M | $448.00K | $-184.83M | $74.67M | 3 month · $798.00K | 3 month · $-484.00K | (m) |
| 2024-12-31 | $469.00K | $258.51M | $448.00K | $-192.21M | $66.33M | 12 month · $4.17M | 12 month · $1.14M | (m) |
| 2024-09-30 | $322.00K | $163.00M | $448.00K | $-178.13M | $-15.26M | 3 month · $1.07M 9 month · $3.21M | 3 month · $110.00K 9 month · $856.00K | (m) |
| 2024-06-30 | $303.00K | $157.66M | $448.00K | $-167.49M | $-9.97M | 3 month · $1.11M 6 month · $2.14M | 3 month · $733.00K 6 month · $746.00K | (m) |
| 2024-03-31 | $292.00K | $151.38M | $448.00K | $-145.25M | $5.98M | 3 month · $1.03M | 3 month · $13.00K | (m) |
| 2023-12-31 | $290.00K | $149.93M | $448.00K | $-137.03M | $12.74M | 12 month · $3.14M | 12 month · $-46.00K | (m) |
| 2023-09-30 | $290.00K | $149.11M | $448.00K | $-125.93M | $23.02M | 3 month · $735.00K 9 month · $2.28M | 3 month · $-49.00K 9 month · $-126.00K | (m) |
| 2023-06-30 | $290.00K | $148.43M | $448.00K | $-117.50M | $30.77M | 3 month · $746.00K 6 month · $1.54M | 3 month · $-13.00K 6 month · $-78.00K | (m) |
| 2023-03-31 | $290.00K | $147.69M | $448.00K | $-107.88M | $39.65M | 3 month · $798.00K | 3 month · $-65.00K | (m) |
| 2022-12-31 | $290.00K | $146.96M | $448.00K | $-99.09M | $47.71M | 12 month · $3.15M | 12 month · $-838.00K | 12 month · $448.00K |
| 2022-09-30 | $290.00K | $146.29M | $448.00K | $-94.01M | $52.13M | 3 month · $757.00K 9 month · $2.31M | 3 month · $-14.00K 9 month · $-636.00K | 9 month · $448.00K |
| 2022-06-30 | $290.00K | $145.55M | $448.00K | $-85.32M | $60.07M | 3 month · $724.00K 6 month · $1.55M | 3 month · $-287.00K 6 month · $-622.00K | 3 month · $448.00K 6 month · $448.00K |
| 2022-03-31 | $287.00K | $144.64M | (m) | $-81.17M | $63.76M | 3 month · $828.00K | 3 month · $-335.00K | (m) |
| 2021-12-31 | $286.00K | $144.15M | (m) | $-80.30M | $64.14M | 12 month · $2.59M | 12 month · $375.00K | (m) |
| 2021-09-30 | $286.00K | $144.59M | (m) | $-81.89M | $62.99M | 3 month · $1.31M 9 month · $2.56M | 3 month · $595.00K 9 month · $845.00K | (m) |
| 2021-06-30 | $117.00K | $22.44M | (m) | $-65.73M | $-43.17M | 3 month · $819.00K 6 month · $1.25M | 3 month · $250.00K 6 month · $250.00K | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | $-27.50M | 3 month · $431.00K | (m) | (m) |
| 2020-12-31 | $116.00K | $20.49M | (m) | $-44.17M | $-23.56M | 12 month · $1.41M | 12 month · $695.00K | (m) |
| 2020-09-30 | (m) | (m) | (m) | (m) | $-14.82M | 3 month · $83.00K 9 month · $134.00K | 9 month · $220.00K | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $-12.34M | 3 month · $83.00K 6 month · $51.00K | 3 month · $220.00K 6 month · $220.00K | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $-10.07M | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $-8.04M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |